Table 4 Ongoing intervention studies aiming to reduce cardiovascular disease in cancer patients; only actively recruiting studies are mentioned (accessed 2021-03-22)
From: Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
ClinicalTrials.gov ID | Population | Intervention | Primary endpoint | Estimated enrollment |
|---|---|---|---|---|
NCT03964142 | BC pts. treatment with anthracyclines and / or anti-HER-2 antibodies | comprehensive cardiac rehabilitation program including supervised exercise training | Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography | 340 |
NCT04476576 | hemato-oncological diseases that initiate chemotherapy | Aerobic exercise Vs Flexibility exercise | Change in systolic longitudinal strain (exercise of flexibility and balance). [Time Frame: 6 months] | 38 |
NCT03850171 | Pts with breast cancer or lymphoma scheduled for anthracycline-based chemotherapy | Exercise Training | Changes from baseline in left ventricular (LV) global longitudinal strain (GLS) [Time Frame: week 13] | 120 |
NCT03787966 | BC pts. scheduled for surgery and adjuvant chemotherapy | Exercise training before or before and after medical treatment | Left ventricular ejection fraction [Time Frame: Participants will be followed over 12 months] | 100 |
NCT03711110 | Elderly pts. Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myelom | Intensive cardiovascular monitoring | All-cause mortality [Time Frame: Two (mid-term analysis) and 5 years of follow-up] | 514 |
NCT03186404 | Pts with BC, lymphoma, leukemia or sarcoma scheduled for anthracycline-based chemotherapy | Atorvastatin | Cardiac MRI measured LVEF within 4 weeks of anthracycline completion | 112 |
NCT04023110 | breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab | Carvedilol | Left Ventricular Ejection Fraction (LVEF) [Time Frame: up to 24 months | 110 |
NCT03265574 | Pts with BC and lymphoma treated with anthracyclines | Enalapril | Cardiac troponin T release [Time Frame: One month after last dose of anthracycline | 170 |
NCT03650205 | cancer pts. treated with anthracyclines | Ivabradine | Ventricular function [Time Frame: 365 days after randomization] Reduction in global longitudinal strain of at least 10% (GLS) | 160 |
NCT04030546 | cancer pts. treated with anthracyclines | Ivabradine | Change in left venticular dysfunction by global longitudinal strain (GLS). [Time Frame: 1, 3 and 6 months] Change in global longitudinal strain (GLS) at least by 3%. | 128 |
NCT04429633 | breast cancer patients treated with adjuvant trastuzumab. | Candesartan | Left ventricular ejection fraction (LVEF) [Time Frame: at months 3,6,9,12,18] | 136 |
NCT02818517 | Two cohorts, one prospective group will include all oncologic patients who will be evaluated in the cardio-oncology clinic | ACE inhibitors or beta blockers | ECho-global strain [Time Frame: 2 years | 1000 |
NCT04092309 | Pts undergoing Hematopoietic Stem Cell Transplantation | Sacubitril-Valsartan | Left Ventricular Function, Global Longitudinal Strain, arterial stiffness, glycocalyx thickness [Time Frame: 2 years] | 90 |
NCT02943590 | Pts with newly diagnosed NHL and HL, anthracycline-based therapy | Atorvastatin | Left ventricular Ejection Fraction (LVEF) [Time Frame: 12 months] | 270 |
NCT04632407 | BC pts. during adjuvant chemotherapy | Dietary Supplement: Flax “milk”Dietary Supplement: Oat fibre “milk” | Left ventricular ejection fraction (LVEF) change [Time Frame: 1 year] | 60 |
NCT03934905 | BC pts. neoadjuvant treatment incl doxorubicin | sulforaphane | Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies [Time Frame: At baseline and 1 year from baseline assessment.] | 70 |
NCT04361240 | Breast cancer radiotherapy | Radiation: Proton vs Photon Radiation | Change in echocardiography derived LVEF from baseline | 155 |